There was no significant difference in GORD(p=0.305), rhinosinus disease(p=0.388) or oral corticosteroid requirement (p=0.6896). Asthma Control Questionnaire (ACQ) was significantly higher in OSA 3.3 \pm 1.3 compared to the no-OSA group 2.8 \pm 1.3, p=0.022 (Apnoea Hypoxia Index (AHI) \geq 10)

Conclusion Asthmatics with co-morbid OSA are more likely to have poor asthma control with significantly higher ACQ scores. Additionally, these patients have significantly higher rates of diabetes, dyslipidaemia and hypertension. Routine screening for OSA and metabolic syndrome ("syndrome z") is recommended in asthmatics.

P196

A NEW QUESTIONNAIRE TO MEASURE QUALITY OF LIFE IN SEVERE ASTHMA (SAQ): PRELIMINARY VALIDATION

¹R Jones, ²M Masoli, ³M Hyland, ¹J Lanario. ¹Peninsula School of Medicine and Dentistry, University of Plymouth, Plymouth, UK; ²Plymouth Hospital's NHS Trust, Plymouth, UK; ³School of Psychology, University of Plymouth, Plymouth, UK


10.1136/thoraxinl-2017-210983.338

Introduction and Objectives Existing HRQoL scales have poor content validity for severe asthma as they fail to measure the qualitatively different burdens experienced by the severe asthma population compared to those with mild or moderate asthma, in particular, the side effects of oral corticosteroids (OCS). A new severe asthma quality of life questionnaire (SAQ) has been designed using extensive patient input in qualitative studies as per FDA guidelines. The questionnaire has 16 questions rated on a 1–7 Likert scale and a 100 point global quality of life scale (GQoL) similar to the EQ-5Ds 100 point visual analogue scale (VAS) (SAQ.org.uk).

Methods Consecutive consenting patients attending the severe asthma clinic in Plymouth with severe asthma were invited to participate in a cross sectional survey. Patients completed four questionnaires the SAQ, mini Asthma Quality of Life Questionnaire (miniAQLQ), Asthma Control Test (ACT) and the EQ-5D. Prednisolone dose and frequency of severe exacerbations were obtained from clinic records.

Results 102 participants (64 female, mean age=51 years range 18–79 years), of whom 38 were on maintenance OCS consented to take part, mean FEV1% of 69%. Correlations between the four questionnaires were all above 0.65. Correlations with frequency of severe exacerbations were SAQ 0.31, miniAQLQ 0.31, ACT 0.34. The SAQ's GQoL correlated with the EQ-5D's VAS at 0.73. The SAQ was significantly better than the miniAQLQ at predicting the quality of life of patients taking $\geq\!10$ mg OCS a day (p<0.05 vs p=0.88). These questionnaires had parallel Results for doses up to 10 mg but above that only SAQ provided differentiation between patients.

Conclusions Preliminary Results indicate that the SAQ may be a more valid measure of quality of life in severe asthma than existing questionnaires. The SAQ maps onto a pre-existing health economic measure, the EQ-5D. Furthermore the SAQ has greater sensitivity to differences in OCS dose compared to the AQLQ. The SAQ will be assessed further in a larger validation study.



Abstract P196 Figure 1

P197

THE IMPROVING ASTHMA CARE TOGETHER (IMPACT)

D Subramanian, S Greenwood, E Dryden, H Paine, S Ali, C Bennet, H Lagnado, L Sutton. Royal Derby Hospital, Derby, UK

10.1136/thoraxjnl-2017-210983.339

and 10=excellent).

The Improving Asthma Care Together (ImpACT) project implements a novel model of care which provides an integrated responsive services for asthma patients in Derby.

Aim The hypothesis of this project was that rapid review by a

specialist asthma nurse in the community during an asthma

exacerbation, would result in an improvement in patient's

asthma control and their ability to self-manage their asthma. Methods Four specialist asthma nurses were recruited to provide seven day cover for the service. Patients who reported increasing asthma symptoms could access the service by self-referral or referral from a healthcare professional. The intervention involved a face-to-face review or a telephone call from a specialist asthma nurse. Patients were offered a 30 min face to face review at a variety of GP locations in the region. A template for each ImpACT review was constructed and a management plan issued at each consultation. A questionnaire was devised and patients were asked to complete this approximately 6 weeks following the intervention. A 10 point scale was used to ask patient's what their confidence levels were in self-managing their asthma (0=no confidence and 10=highly

Results This project commenced in January 2017. Between the start date and June 2017 a total of 884 patients were reviewed as part of the service. 397 face-to- face visits, 470 telephone consultations and 17 home visits. Patient's self-rating of their asthma control significantly improved following the intervention (pre-intervention mean 3.4, standard deviation [SD] 2.2 versus post-intervention mean 8.1 [SD 1.4]; paired t-test <0.001; n=23). Patient's self-reported confidence in

confident) and how they rated their asthma control (0=poor

Thorax 2017;**72**(Suppl 3):A1–278